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Summary
Germ-line mutations of the tumor suppressor APC are
implicated in attenuated adenomatous polyposis coli
(AAPC), a variant of familial adenomatous polyposis
(FAP). AAPC is recognized by the occurrence of !100
colonic adenomas and a later onset of colorectal cancer
(age 140 years). The aim of this study was to assess
genotype-phenotype correlations in AAPC families. By
protein-truncation test (PTT) assay, the entire coding
region of the APC gene was screened in affected indi-
viduals from 11 AAPC kindreds, and their phenotypic
differences were examined. Five novel germ-line APC
mutations were identified in seven kindreds. Mutations
were located in three different regions of the APC gene:
(1) at the 5′ end spanning exons 4 and 5, (2) within exon
9, and (3) at the 3′ distal end of the gene. Variability in
the number of colorectal adenomas was most apparent
in individuals with mutations in region 1, and upper-
gastrointestinal manifestations were more severe in
them. In individuals with mutations in either region 2
or region 3, the average number of adenomas tended to
be lower than those in individuals with mutations in
region 1, although age at diagnosis was similar. In all
AAPC kindreds, a predominance of right-sided colorec-
tal adenomas and rectal polyp sparing was observed. No
desmoid tumors were found in these kindreds. Our data
suggest that, in AAPC families, the location of the APC
mutation may partially predict specific phenotypic ex-
pression. This should help in the design of tailored clin-
ical-management protocols in this subset of FAP
patients.
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Introduction
Familial adenomatous polyposis (FAP) is an inherited,
autosomal dominant syndrome caused by germ-line mu-
tations of the adenomatous polyposis coli (APC) gene,
APC (Groden et al. 1991; Kinzler et al. 1991). Clinical
diagnosis of FAP is usually based on the presence of 1100
colonic adenomas (Bussey 1975), which, if left un-
treated, progress to colorectal cancer (CRC), typically
at age X40 years (Gardner 1951). Other features include
variable age at onset of polyposis (age 10–40 years) and
variable expressivity (Groden et al. 1993; Giardiello et
al. 1994). Extracolonic manifestations in FAP include
the occurrence of desmoids, congenital hypertrophic ret-
inal pigment–epithelial lesions (CHRPE), upper-gastro-
intestinal (UGI) polyps, and cancers of the thyroid,
brain, and hepatobiliary tract. In previous studies, as-
sociation of colonic polyposis and CRC with osteomas,
fibromas, or epidermoid cysts has been described as a
distinct entity, “Gardner syndrome” (Gardner and Rich-
ards 1953). That FAP and Gardner syndrome are the
same genetic entity became apparent with the discovery
of the APC gene and the identification of germ-lineAPC
mutations in patients with those syndromes.
APC is a large (∼300 kD) multifunctional protein and
consists of distinct sequence motifs that specify its in-
teractions with diverse protein partners (Polakis 1997).
The majority of germ-line APC mutations cause trun-
cated products and predominantly occur in the first half
of the gene (Nagase et al. 1992a). Some phenotypic var-
iants of FAP have been specifically associated with dis-
tinct mutation patterns in the APC gene. Thus, the oc-
currence of CHRPE is correlated with APC mutations
in the region spanning exons 9–15 (Olschwang et al.
1993b), and the desmoid tumors are correlated with
mutations in the region spanning codons 1444–1578
(Caspari et al. 1995). With regard to colonic adenoma-
tous polyposis, a “sparse” phenotype (1,000–2,000 pol-
yps) has been correlated with germ-line APC mutations
in the region spanning codons 213–1597 (Nagase et al.
1992a); whereas a “profuse” (15,000 polyps) phenotype
has been demonstrated to segregate withAPCmutations
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in the region spanning codons 1250–1464 (Nagase et
al. 1992b; Caspari et al. 1994; Gayther et al. 1994).
Recognition of such genotype-phenotype associations,
along with the identification of distinct structural motifs,
has provided important insights into APC’s function. For
example, APC carries a series of b-catenin–binding sites
in the region associated with profuse polyposis. Using
these sites, APC regulates intracellular turnover of b-
catenin (Su et al. 1993), a protein involved in cellular
adhesion, communication, and cell signaling pathways
that affect apoptosis and cell growth (Hu¨lsken et al.
1994; Morin et al. 1996, 1997; Peifer 1996; Rubinfeld
et al. 1996; Korinek et al. 1997). Thus, mutant APC
transcripts with deletions of the b-catenin–binding re-
gion function by mediating an imbalance of cell division
over cell death, which likely results in an aggressive
polyposis phenotype. Another functional domain, lo-
calized to the first 55 residues of APC, is involved in the
protein-dimerization process (Joslyn et al. 1993). Mu-
tation analyses have shown this domain to be almost
always retained in the truncated mutant APC tran-
scripts, which suggests that the dimerization domain is
critical to APC’s function.
Attenuated APC (AAPC) is a variant of FAP (Leppert
et al. 1990) and also has been described as “hereditary
flat adenoma syndrome” (Lynch et al. 1988, 1995).
AAPC differs phenotypically from classical FAP, in the
number of colonic adenomas (usually !100) that tend
to be located proximal to the splenic flexure (van der
Luijt et al. 1996; Giardiello et al. 1997; Gardner et al.
1997). These adenomas may present with a flat (rather
than polypoid) morphology. Gastric fundic polyps and
duodenal adenomas are also seen, and, in contrast to
what is seen in FAP, CHRPE lesions and desmoid tumors
rarely have been described in AAPC (Lynch et al. 1995;
Scott et al. 1995). The average age at onset of CRC is
later in AAPC (average age 55 years) than in classical
FAP (average age 39 years) (Lynch et al. 1995). Fur-
thermore, some AAPC families may phenotypically over-
lap with the hereditary nonpolyposis CRC syndrome
(HNPCC), in which adenomas also are located on the
right side of the colon (Jass et al. 1994). Alternatively,
in some small nuclear AAPC families, the lack of ac-
curate documentation regarding the number and/or the
location of polyps may lead to a misdiagnosis of sporadic
CRC.
In 1992, the attenuated variant was localized to the
APC gene locus by molecular-genetic linkage analysis
(Spirio et al. 1992). These observations were subse-
quently confirmed by the identification of four distinct
germ-line mutations occurring at the 5′ end of the APC
gene (Spirio et al. 1993). Several reports have described
AAPC families with unique APC mutations (Cama et al.
1994; Dobbie et al. 1994; Smith-Ravin et al. 1994; Va-
resco et al. 1994; van der Luijt et al. 1995; Giardiello
et al. 1997); however, only a few studies have investi-
gated genotype-phenotype associations in AAPC (Spirio
et al. 1993; Giardiello et al. 1997). In the present study,
we used molecular-genetic characterization of APC to
better classify kindreds that have a familial predisposi-
tion to colonic adenomas and CRC and that have phe-
notypic features not typical of FAP or HNPCC.
Subjects and Methods
Selection of Patients
Eleven unrelated kindreds with hereditary predispo-
sition to colonic adenomas and CRC were identified,
from the Familial Gastrointestinal Cancer Registry lo-
cated at our institution. Most affected individuals had
110 but !100 adenomas, and 9 of 11 families had a
history of CRC. Endoscopic, operative, and histopath-
ological data were collected retrospectively. Complete
follow-up information was obtained as well. Predictive
genetic testing was offered to affected individuals, with
pre- and posttest counseling (Soravia et al. 1997a). Pa-
tient accrual, sample collection, and genetic screening
were performed according to guidelines of the Human
Ethics Committee of the University of Toronto.
Molecular-Genetic Analysis
The protein-truncation test (PTT) assay was used to
screen for APC germ-line mutations (Powell et al. 1993;
van der Luijt et al. 1994). Blood samples were obtained
from affected individuals, and lymphoblastoid Epstein-
Barr virus–transformed cell lines were established for
some of these patients. RNA and DNA extraction was
performed by use of TRIzolJ and DNAzolJ, according
to the manufacturer’s protocol (Life Technologies). Re-
verse-transcription PCR was performed by use of stan-
dard techniques. In brief, cDNA was generated from
total RNA (2–5 mg) by use of random hexamers, 1 #
first-strand buffer, 0.5 mM of deoxynucleotide triphos-
phate, 10 mM DTT, and 200 units of Superscript II
reverse transcriptase (Bethesda Research Laboratories).
cDNA and genomic DNA were amplified under the fol-
lowing conditions: initial denaturation at 95C for 2
min; 35–40 cycles, each consisting of denaturation at
95C for 30 s, annealing at 63C–65C for 1 min 30 s,
and extension at 70C for 2 min; and a final extension
at 70C for 5 min. Five-microliter aliquots of PCR prod-
ucts were electrophoresed on a 1.5% agarose gel, in
order to confirm amplification.
The in vitro–synthesized PTT assay was performed by
use of a commercial kit (TNT7 T7 Quick Coupled Tran-
scription/Translation System; Promega), according to the
manufacturer’s protocol. In brief, APC exon 15 was am-
plified in four overlapping segments, as described else-
where (Powell et al. 1993). Exons 1–14 were amplified
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Table 1
Characterization of APC Mutations
Kindred(s) Exon Nucleotide Change Consequence





4 4 CAGrTAG CrT substitution,
Glnrstop, nucleo-
tide 487
5 9 ATGTrTGT Deletion of A, frame-
shift; termination
at nucleotide 1014
6 9 CGArTGA CrT substitution,
Argrstop, nucleo-
tide 994
7 15 TCCGrTCG Deletion of C, frame-
shift, termination
at nucleotide 6218
Figure 1 Representative PTT analysis for APC segment 1A (co-
dons 1–379) (lanes 1, 2, and 5–7) and APC segment 1 (codons 1–811)
(lanes 3 and 4). The size of the protein marker is shown. The single
arrow in the left-hand panel indicates truncated mutant protein. Lanes
2, 3, and 6, Non-FAP controls. Lane 1, Kindred 1. Lane 4, Kindred
2. Lane 7, Kindred 3. Lane 5, Kindred 4. WT  wild type.
in two overlapping segments: 1A (exons 1–9) and 1B
(exons 8–14). The 5′ end of each forward primer had a
T7 promoter sequence and a translation-initiation site
for coupled in vitro transcription and translation. PCR
products were separated on 12.5% polyacrylamide gels.
Positive PTT results were confirmed by two independent
PCR reactions.
For sequence determination, PCR products of the pu-
tative positive-PTT samples were electrophoresed on a
1.5% agarose gel for 45–60 min at 100 V and were
stained with ethidium bromide. The band of interest was
excised with a sterile scalpel blade, and DNA was ex-
tracted by use of the QIAquick Gel Extraction Kit (QIA-
GEN). The dideoxy-mediated chain-termination method
was used for DNA sequencing (Sanger et al. 1977). For
this purpose, we used a[33P] dideoxynucleotide and a
ThermoSequenase radiolabeled terminator sequencing
kit (Amersham Life Science); sequencing was performed
according to the manufacturer’s protocol. Finally, the
gel was autoradiographed by use of BioMax MR film
(Kodak) for 24–48 h at room temperature. Additional
confirmation was obtained by genomic DNA sequenc-
ing. Primers used for PTT-PCR and sequencing reactions
are available on request.
Results
In 7 of the 11 kindreds, putative truncating mutations
were identified as novel transcripts, by PTT analysis.
Sequence characterization revealed five germ-line APC
mutations in these seven families (table 1). To the best
of our knowledge, all five APC mutations are novel (Be´-
roud and Soussi 1996; De Vries et al. 1996). In three
AAPC kindreds, a truncated-protein product of ∼16 kD
was identified, in addition to the wild-type protein for
APC segments 1 (codons 1–811; fig. 1A, lanes 3 and 4)
and 1A (codons 1–379; figs. 1A, lanes 1 and 2, and 1B,
lanes 5–7). Sequence analysis revealed this truncation to
be caused by exon 4 deletion, leading to a frameshift
mutation and resulting in a stop codon (TGA) at nu-
cleotide 551 (codon 184). In kindred 4, the size of the
novel PTT product was ∼20 kD (fig. 1B, lane 5). DNA
sequence analysis revealed a CrT transversion at nu-
cleotide 487 (exon 4, codon 163), resulting in a substi-
tution of glycine by a stop codon (CAGrTAG). In kin-
dreds 5 and 6, the truncated proteins showed a similar
pattern (doublet), ∼46 kD in size (fig. 2A). Subsequent
characterization by sequencing identified two distinct
APC germ-line mutations within exon 9. Specifically, in
kindred 5, the mutation occurred at nucleotide 988 (de-
letion A), resulting in a frameshift leading to a stop co-
don (TAG) at nucleotide 1014, and, in kindred 6, a CrT
transversion at nucleotide 994 resulted in a substitution
of arginine by a stop (GCArTGA) at codon 332. Finally,
in kindred 7, the size of the truncated protein was ∼48
kD (fig. 2B). By sequence analysis, the mutation was
identified to be a 1-bp frameshift deletion (C) at APC
nucleotide 6138 (codon 2047), leading to a stop codon
(TGA) at nucleotide 6218.
Tables 2–4 summarize phenotypic and clinical data
on the seven kindreds, according to the location of the
APC mutations. Kindred 2 is a large AAPC family and
spans four generations with 27 affected individuals. In
this family, a variability was observed with respect to
the number of colorectal adenomas (mean 142, range
2–580). A predominance of right-sided colonic polyps
with rectal sparing was observed in all AAPC families.
In kindreds with 5′-end APC mutations (table 2), the
mean age at polyposis diagnosis was 42 years (range
39.5–45.2 years), with a mean of 96 polyps (range
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Figure 2 Representative PTT analysis for APC segment 1A (co-
dons 1–379) (lanes 8–12) and APC segment 4 (codons 1555–2256)
(lanes 13–15). The size of the protein marker is shown. The single
arrow in the left-hand panel indicates truncated mutant protein. Lanes
9, 12, 13, and 15, Non-FAP controls. Lane 8, Kindred 5. Lanes 10
and 11, Kindred 6. Lane 14, Kindred 7. WT  wild type.
1–580), and the mean age at CRC diagnosis was 58.1
years (range 29–76). In the group with mutations inAPC
exon 9, although both the mean age at polyposis di-
agnosis (39.7 years [range 12–64]) and the mean age at
CRC diagnosis (54.2 years [range 42–67]) were com-
parable to those in the first group, the average number
of polyps (22 [range 1–150]) was less (table 3). In the
AAPC kindred with 3′-end APC mutations, mean age at
polyposis diagnosis was 49 years (range 41–65), and
mean number of colonic polyps was 14 (range 1–36);
thus far, no CRC has been diagnosed in this family
(table 4).
Discussion
In this study, we have shown that AAPC is caused by
mutations in three distinct regions of the APC
gene—that is, at the 5′ end, in the region spanning exons
4 and 5; in exon 9; and at the extreme 3′ end. Phenotypic
expression in these three groups of kindreds is variable
but is definitely milder than that in classical FAP, indi-
cating modified clinical-management protocols for af-
fected AAPC patients and their at-risk relatives. Our
data demonstrate that AAPC families carrying 5′ germ-
line APC mutations exhibit greater variability with re-
gard to the frequency and age at onset of polyposis, such
that the phenotypes of some affected patients are quite
similar to that of classical FAP. Furthermore, duodenal
adenomas occur with an increased severity in these
families.
We have identified four AAPC kindreds with APC
mutations located proximal to codon 168. Of these four
kindreds, three carry the same APC mutation, and the
fourth carries a truncating mutation within APC exon
4. To date, 13 AAPC families with germ-line APC mu-
tations proximal to codon 168 have been described (Spi-
rio et al. 1993; Olschwang et al. 1993a; Giardiello et
al. 1997). 5′ APC mutations predict the synthesis of pro-
teins shorter than those predicted from the APC mu-
tations commonly associated with classical FAP (Horii
et al. 1993; Samowitz et al. 1995). Therefore, different
properties of the two types of mutant APC proteins may
be expected (Fodde and Meera Khan 1995). Short APC
peptides may be unable to compete with other peptide
complexes, because of a lack of essential sequence motifs
required for such protein-protein interaction. Alterna-
tively, such alleles are likely to be unstable and may result
in null alleles.
Two AAPC kindreds carry APC mutations in exon 9.
This exon is usually alternatively spliced. Germ-line mu-
tations in APC exons 6 and 9A, including those causing
a splice-site defect, have been reported in AAPC families
(Cama et al. 1994; Smith-Ravin et al. 1994; Varesco et
al. 1994; van der Luijt et al. 1995). Mutations occurring
in alternatively spliced regions of APC would support
the haploinsufficiency model, in which an unstable trun-
cated mutant protein with a reduced amount of normal
APC induces a less severe phenotype (Fodde and Meera
Khan 1995; Yang et al. 1997). Furthermore, the splice-
site mutations of such APC exons are thought to pro-
voke inefficient exon skipping, which may be responsible
for the delay in the development of colonic polyposis
(Varesco et al. 1994). In the present study, although the
mutations in exon 9 were located outside the alterna-
tively spliced region, the phenotypes of these two kin-
dreds are typical of AAPC (table 3). Average age at di-
agnosis of polyposis is 40 years, and usually there are
!100 right-sided colonic adenomas, with rectal-polyp
sparing; gastric/duodenal manifestations were not ob-
served in these families.
We found one kindred with a germ-lineAPCmutation
at codon 2047, which appears to be one of the most 3′
mutations reported in AAPC. In this kindred, the colonic
phenotype is very mild, with !40 polyps, no CRC, and
rectal-polyp sparing (table 4). Previous studies have
shown that germ-line mutations at the distal 3′ end of
APC correlate with the AAPC phenotype (Scott et al.
1995; Friedl et al. 1996; van der Luijt et al. 1996; Gard-
ner et al. 1997). Such mutant APC transcripts are likely
to be proficient in b-catenin binding, thereby mediating
signals that are important for cell adhesion and turnover
(Friedl et al. 1996). Alternatively, 3′-mutant APC pro-
teins are likely to form stable homodimers and to retain
partial function, as in the case of “leaky” mutant alleles
(Spirio et al. 1993). Kindreds with desmoid tumors but
with almost no colonic manifestations have been re-
ported recently (Eccles et al. 1996; Scott et al. 1996).
These families are noteworthy for having APC muta-
tions in the 3′ region of the gene. This variant of FAP
has been termed “hereditary desmoid disease” and pre-
viously had been classified as “familial infiltrative fibro-
matosis” (MIM 135290). In these kindreds, CRC oc-
Table 2









II-1 (F) 59 Absent ()) Multiple (both sides of
colon [more on right side])
Ileo-rectal anastomosis Not reported )
III-1 (M) 55 Present (right side [two]) ) Right-side colectomy Not reported )





III-5 (M) 48 (57) Absent ()) Multiple (both sides of
colon [more on right side])
Ileo-rectal anastomosis Not reported Rectum clear (4 years)
III-7 (F) 43 Absent ()) 150 (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis Ampullectomy Rectum clear (20 years)
III-8 (F) 41 Absent ()) 384 (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis Not reported )
IV-2 (F) 33 Absent ()) 25 (both sides of colon [more on
right side])
Ileo-rectal anastomosis Not reported )
IV-5 (M) 42 Absent ()) 5 (both sides of colon [more on
right side])
Ileo-rectal anastomosis Not reported )
IV-26 (F) 40 Absent ()) 20 (both sides of colon [more on
right side])
None UGI normal )
IV-30 (M) 24 Absent ()) 28 (both sides of colon [more on
right side])
Ileo-rectal anastomosis Not reported Rectum clear (13 years)
IV-32 (M) 36 Absent ()) 100 (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis Not reported )
V-28 (F) 19 Absent ()) 41 (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis UGI normal Rectum clear (2 years)
2:
III-2 (F) 57 Absent ()) !100 (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis UGI normal )
III-6 (M) 59 Present (left side of colon) Multiple (left side of colon) Ileo-rectal anastomosis Not reported )









Not reported Local cancer recurrence
IV-1 (F) 41 Absent ()) Multiple (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis Not reported )




Duodenal cancer Liver metastases
IV-3 (F) 38 Absent ()) Multiple (both sides of colon
[more on right side])
Ileo-rectal anastomosis UGI normal )
IV-4 (M) 37 Absent ()) !100 (both sides of colon [more
on right side])
Ileo-rectal anastomosis UGI normal Rectum clear (12 years)







[years] CRC Status (Location) No. (Location) of Adenomas Surgery
Extracolonic
Manifestations Postsurgical Follow-up
IV-8 (M) 27 Absent ()) Multiple (both sides of colon
[more on right side])
Ileo-rectal anastomosis Not reported )





IV-23 (F) 37 Absent ()) !150 (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis Not reported Rectum clear (4 years)
IV-29 (F) 29 (46) Present (left side of colon) ) Left-side colectomy Not reported )
Present (right side of colon) 2 (right side of colon) Right-side colectomy Not reported Retroperitoneal metastases





IV-37 (F) 46 Absent ()) 69 (both sides of colon [more on
right side])
Ileo-rectal anastomosis Not reported )
IV-43 (F) 46 (49) Present (right side of colon) Multiple (both sides of colon
[more on right side])
Ileo-rectal anastomosis Not reported Liver metastases
IV-45 (M) 50 (53) Present (left side of colon) Multiple (both sides of colon
[approximately equal amounts])
) UGI normal Liver metastases
IV-47 (M) 44 Present (right side of colon) !100 (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis Not reported )
IV-51 (M) 38 Present (left side of colon) !100 (both sides of colon [more
on right side])






V-7 (M) 20 Absent ()) 7 None Not reported )
V-21 (F) 37 Absent ()) !100 (both sides of colon [more
on right side])
Ileo-rectal anastomosis Not reported )
V-25 (M) 29 Absent ()) !200 (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis UGI normal Rectum clear (2 years)
V-32 (F) 23 Absent ()) 580 (both sides of colon [more
on right side])
Ileo-rectal anastomosis Not reported )
V-34 (F) 38 Absent ()) 300 (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis Not reported )
V-37 (F) 33 Absent ()) 200 (both sides of colon [more
on right side])
Ileo-rectal anastomosis UGI normal )
V-40 (F) 28 Absent ()) !100 (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis UGI normal Rectum clear (1 year)
V-59 (M) 19 Absent ()) 6 (both sides of colon
[approximately equal amounts])
None UGI normal )
3:
I-1 (F) 76 (77) Present (left side of colon) Not reported Left-side colectomy Not reported )











II-2 (F) 71 (71) Present (right side of colon) Not reported Right-side colectomy Not reported Liver metastases
II-3 (F) 64 Present (left side of colon) Not reported Left-side colectomy Not reported )
III-4 (F) 52 Absent ()) 100 (both sides of colon [more
on right side])
Ileo-rectal anastomosis UGI normal )
III-9 (F) 51/52 Absent ()) 200 (both sides of colon [more
on right side])
Ileo-rectal anastomosis Not reported )
III-12 (M) 33 Absent ()) 3, right side of colon Right-side colectomy Not reported )
4:
I-1 (M) (60) Present (not reported) Not reported Colostomy Not reported )
II-1 (M) 35 (69) Present (left side of colon) Not reported Ileal pouch–anal
anastomosis
UGI normal )
II-3 (F) 66 Absent ()) 50 (both sides of colon [more on
right side])
Ileo-rectal anastomosis Duodenal polypectomy )
II-7 (M) 58 Absent ()) 100 (both sides of colon
[approximately equal amounts])
Left-side colectomy Not reported 6 Polyps, right side of colon
III-2 (M) 37 Absent ()) 40 (both sides of colon [more on
right side])
Right-side colectomy Not reported Normal colonoscopy
III-10 (M) 30 Absent ()) 1, excised (right side of colon) ) Not reported Normal colonoscopy
Table 3









III-2 (M) 60 Present (left side of colon [two]) Not reported Ileo-rectal anastomosis Not reported )
64 (64) Present (rectum) Not reported Proctocolectomy with
end ileostomy
Not reported Liver metastases
III-3 (M) 50 Present (left side of colon) Not reported Not reported Not reported )
III-4 (M) 55 (71) Absent ()) Multiple (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis UGI normal Lung cancer
III-5 (M) 43 Present (right side of colon) ) Right-side colectomy Not reported )
58 Absent ()) 21 (left side of colon) Left-side colectomy UGI normal )
III-6 (M) 53 Absent ()) 8 (both sides of colon [more on
left side])
Ileo-rectal anastomosis UGI normal Rectum clear (26 years)
III-9 (F) 44 Absent ()) Multiple (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis UGI normal Rectum clear (24 years)
IV-2 (M) 39 Absent ()) Multiple (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis Not reported Rectum clear (23 years)
IV-9 (M) 41 (47) Absent ()) 2, right side of colon Ileo-rectal anastomosis Not reported Esophageal cancer
IV-10 (F) 36 Absent ()) 150 (both sides of colon [more
on right side])
Ileo-rectal anastomosis UGI normal Rectum clear (13 years)
IV-11 (F) 50 Absent ()) ) ) ) )
IV-12 (M) 37 Absent ()) 2 (both sides of colon [approxi-
mately equal amounts])
) Not reported )
IV-17 (F) 27 Absent ()) 20 (both sides of colon [more on
right side])
Ileo-rectal anastomosis UGI normal Rectum clear (23 years)
IV-18 (M) 16 Absent ()) Multiple (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis UGI normal Rectum clear (24 years)
IV-20 (M) 41 Absent ()) 2 (left side of colon) ) Not reported )
V-1 (M) 36 Absent ()) 28 (both sides of colon [more on
right side])
Ileo-rectal anastomosis Not reported Rectum clear (1 year)
V-7 (M) 35 Absent ()) Multiple (both sides of colon
[approximately equal amounts])
Ileo-rectal anastomosis Not reported Rectum clear (4 years)
V-10 (F) 12 Absent ()) 1 (left side of colon) ) Not reported )
6:
II-1 (F) 67 Present (left side of colon) None Left-side colectomy Not reported )
III-1 (F) 42 Present (left side of colon) 27 (both sides of colon [more on
right side])
Left-side colectomy UGI normal Cervical metastases
III-2 (F) 43 Absent ()) 43, right side of colon Ileo-rectal anastomosis Not reported Rectum clear (1 year)
III-4 (F) 35 Absent ()) 20 Ileo-rectal anastomosis Not reported )
IV-1 (M) 25 Absent ()) 10 (both sides of colon [more on
right side])
) Not reported )
IV-2 (F) 30 Absent ()) 2 (both sides of colon [approxi-
mately equal amounts])
) Not reported )
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Table 4

















Rectum clear (1 year)
IV-9 (M) 47 Absent ()) 1 (left side of
colon)
) Not reported )









Ileo-rectal anastomosis Not reported )
casionally occurs without obvious polyposis. This subset
of kindreds could therefore also be considered an AAPC
variant with predominance of desmoid tumors. Indeed,
in classical FAP, families with desmoid tumors and with-
out CHRPE have been reported to have germ-line mu-
tations in the region of APC codons 1445–1578 (Hodg-
son et al. 1994; Caspari et al. 1995). In our AAPC
kindreds, desmoid tumors have not been identified.
A germ-line APC mutation was not identified in 4 of
11 kindreds. There are a number of possible explana-
tions: the PTT assay may be unable to detect all mu-
tations in these genes; the mutations may be located in
a gene region (e.g., intronic or promoter regions) that
was not investigated, or a mutation in a gene(s) other
than APC may be the underlying defect in these families.
Two phenotypic features of our AAPC families are
worth emphasizing: (1) we observed rectal-polyp sparing
in patients who underwent total colectomy and ileo-
rectal anastomosis, after a mean follow-up period of
11.7 years (range 1–26 years); and (2) we also observed
an increased trend toward development of gastric and
duodenal adenomas, with the occurrence of duodenal
cancer in one case, as reported elsewhere (Soravia et al.
1997b; Zwick et al. 1997). Clinical review of AAPC
families with 5′-end APC mutations (table 2) demon-
strates that, although the number of colorectal adeno-
mas usually is !100, in some cases variability is observed
with regard to the number of colonic polyps (i.e., there
are 1100), with a predominance of polyps located on
the right side, as has been described elsewhere (Burt et
al. 1995). In families described here, the average age at
CRC diagnosis is ∼58 years, whereas the average age at
polyposis diagnosis is 42 years; these observations are
in agreement with other reports (Dobbie et al. 1994;
Lynch et al. 1995; Giardiello et al. 1997).
Differences in the APC mutation sites alone cannot
completely account for intra- and interfamilial variation
in the polyposis phenotypes in these families. Another
likely explanation for phenotypic variability is the pres-
ence of a modifier gene(s) that may influence the phe-
notypic expression of the APC gene. Such a gene is prob-
ably comparatively polymorphic, since phenotypic
variability occurs both within and between families. For
example, a modifier gene located on chromosome 1p35-
36 may influence the severity of duodenal polyposis in
FAP (Tomlinson et al. 1996; Dobbie et al. 1997). It is
also likely that environmental factors, such as diet, play
an important role in AAPC, as has been demonstrated
in the mouse models of FAP (Hioki et al. 1997).
The use of molecular-genetic testing has been sug-
gested as an aid in decision making with respect to the
type of surgical procedure (total colectomy vs. restora-
tive proctocolectomy) based on the risk of rectal cancer
in FAP (Vasen et al. 1996). This suggestion has been
challenged by others (Gareth et al. 1997), because few
relevant clinical data had been given to support it. The
lifetime risk for development of CRC has not yet been
estimated in AAPC. Therefore, clinical decision making
with respect to the type of surgical procedure should
rely on a combination of factors, including age at AAPC
diagnosis, number of adenomas (120), location of polyps
(right-side colon), frequency of polyp recurrence, and
polyp morphology (confluent vs. scattered polyps). A
patient’s compliance with the clinical-surveillance regi-
men should also be taken into account. Finally, this in-
formation needs to be correlated with the molecular di-
agnosis of AAPC in affected and/or presymptomatic
individuals of such kindreds.
In view of our experience, the following information
seems relevant for the clinical management of AAPC
kindreds: (1) predictive genetic testing can be offered to
presymptomatic relatives in AAPC families with a
known germ-line mutation; (2) colonoscopy, as opposed
to sigmoidoscopy, should be advised for endoscopic sur-
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veillance, because of the right-side location of colorectal
adenomas; (3) UGI endoscopic surveillance is warranted
in an attempt to detect premalignant gastric or duodenal
tumors; and (4) individuals affected with AAPC may
require total colectomy with ileo-rectal anastomosis only
when prophylactic colectomy is advised. Finally, the rare
occurrence of rectal polyps in AAPC is noteworthy; how-
ever, further clinical studies with longer follow-up are
needed in order to prove that the risk of rectal cancer
is lower in AAPC than in classical FAP (Nugent and
Phillips 1992).
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